Wed, Apr 16, 2014, 10:03 AM EDT - U.S. Markets close in 5 hrs 57 mins


% | $
Quotes you view appear here for quick access.

Isis Pharmaceuticals, Inc. Message Board

viking99969 21 posts  |  Last Activity: Apr 9, 2014 4:25 PM Member since: Aug 16, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Predicted impact for Vascepa of gsk's lovaza going generic today on Vascepa sales?

  • viking99969 viking99969 Apr 9, 2014 4:22 PM Flag

    Why do you think TEVA's CD sales force exists or is any better than a diligent gorilla? Don't you think TEVA will be preoccupied with the generic lovaza launch FDA approved today?

  • Strange that MDCO didn't disclose these results in a company PR.

    HEAT-PPCI: Heparin Bests Bivalirudin in STEMI, Amid Heated Debate

    The single-center randomized trial of unfractionated heparin vs bivalirudin (Angiomax, the Medicines Company) (with bailout GPIIb/IIIa inhibitors) in STEMI patients surprised attendees on the last day of the ACC meeting by showing a significantly lower rate of major adverse cardiac events (MACE) in the heparin-treated patients at 28 days and no differences in bleeding complications....

    ...In the heparin group, patients received a bolus dose of 70 units/kg preprocedure, while bivalirudin was given as a bolus of 0.75 mg/kg, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.

    At four weeks, the primary efficacy end point (MACE, defined as all-cause mortality, cerebrovascular accident, reinfarction, or unplanned target lesion revascularization [TLR]) had occurred in 8.7% of bivalirudin-treated patients and in 5.7% of heparin-treated patients, an absolute increased risk of 3%.

    Key drivers of this MACE increase were reinfarction and TLR, which were both significantly increased in the bivalirudin group. Definite or probable stent thrombosis was 3.4% in the bivalirudin group and 0.9% in the heparin group (RR 3.91, 95% CI 1.6–9.5; p=0.001).

    Minor bleeds, as well as major/minor bleeds, were no different between groups. Bailout GP IIb/IIIa-inhibitor use was similar in both groups, at 13.5% in the bivalirudin group and 15.5% in the heparin-treated patients.

  • Reply to


    by rmoore15193 Mar 28, 2014 11:41 AM
    viking99969 viking99969 Apr 3, 2014 4:08 PM Flag

    none of them good about your thought

  • Reply to


    by howiviewthis Apr 2, 2014 5:23 PM
    viking99969 viking99969 Apr 3, 2014 4:05 PM Flag

    Careful about who you miss, Ghosts have a way of arising so let's not even take notice, eh?

  • Reply to

    Time for CMI to announce a stock split

    by rw80 Mar 31, 2014 11:15 AM
    viking99969 viking99969 Apr 2, 2014 3:39 PM Flag

    Please explain Why??? A stock priced at $150 a share that splits into 3x$50 just rewards day trading behavior instead of investor behavior. A heavy industrial stock needs investors not briefly traders.

    Sentiment: Buy

  • Reply to

    AGGRASTAT (tirofiban) us patent expired?

    by egmons2003 Mar 28, 2014 11:37 AM
    viking99969 viking99969 Mar 31, 2014 11:24 AM Flag

    Here is a strange thought for your weird question....why don't you look it up yourself and find how weird your question is?

  • History of complaints against cardiac drugs?

    A study published in 2010 determined that "...meta-analysis of randomised controlled trials suggests that ARBs are associated with a modestly increased risk of new cancer diagnosis. Given the limited data, it is not possible to draw conclusions about the exact risk of cancer associated with each particular drug. These findings warrant further investigation." [19] A later meta-analysis by the FDA of 31 randomized controlled trials comparing ARBs to other treatment found no evidence of an increased risk of incident (new) cancer, cancer-related death, breast cancer, lung cancer, or prostate cancer in patients receiving ARBs.[20] In 2013, comparative effectiveness research from the United States Department of Veterans Affairs on the experience of more than a million Veterans found no increased risks for either lung cancer [21] (original article in Journal of Hypertension) or prostate cancer [22] (original article in The Journal of Clinical Pharmacology). The researchers concluded "In this large nationwide cohort of United States Veterans, we found no evidence to support any concern of increased risk of lung cancer among new users of ARBs compared with nonusers. Our findings were consistent with a protective effect of ARBs." [21]
    However in May 2013, a senior regulator at the Food & Drug Administration, Medical Team Leader Thomas A. Marciniak, announced that his examination of all studies of possible ARB/Cancer links failed to include Lung Carcinoma as a "cancer", and the results of his investigation actually showed that lung-cancer risk increased by about 24% in ARB patients, compared with patients taking a placebo or other drugs. An article on these findings by Dr. Marciniak (who served his residency studying cancer at The Mayo Clinic, and then spent 10 years at the National Cancer Institute before going to work at the FDA) was published in the Wall Street Journal on May 30, 2013: [23]
    In the article Ellis Unger, chief of the drug-evaluation division that includes Dr. Marciniak, was quoted as calling the complaints a "diversion," and saying in an interview, "We have no reason to tell the public anything new."
    Some studies have shown links between the entire class of ARB drugs and cancer, while other studies have found no link. Gross revenues of this class of drugs exceed 7 billion dollars a year.

  • viking99969 viking99969 Feb 28, 2014 5:24 PM Flag

    What's the downside to AMRN's suing? They can't be any more cruel than they have already.

  • viking99969 viking99969 Feb 28, 2014 5:23 PM Flag

    Suing the FDA is done all the time - take a look at MDCO's case suing for FDA/USPTO when they missed a deadline by one freekin day.......

  • Reply to

    do you think low $27's was a good entry point?

    by cahi55 Jan 7, 2014 12:35 PM
    viking99969 viking99969 Feb 28, 2014 5:14 PM Flag

    Thought today, Feb 28, was a far better day to take advantage of a dip due to annual earnings report. Who cares about earnings when they have no commercial product approved? More important is their burn rate vs milestones which Bill says they have covered. Traders sold Investors bought

    Sentiment: Buy

  • viking99969 viking99969 Feb 20, 2014 12:14 PM Flag

    Wow, nice call that came two weeks before actual!

  • I'm betting that the "corporate" referred to is not MCD in IL but the store's franchise corporate office. Bet the owner didn't make the call but some flunky son-in-law PO'd he was being disturbed. Prove me wroing.....

  • Reply to

    MCDumb move....

    by rkemily3 Feb 19, 2014 2:26 AM
    viking99969 viking99969 Feb 19, 2014 10:31 PM Flag

    I'm betting that the "corporate" referred to is not MCD in IL but the store's franchise corporate office. Bet the owner didn't make the call but some flunky son-in-law PO'd he was being disturbed. Prove me wroing.....

  • Reply to

    What is Teva

    by bottomfeeder0103 Feb 17, 2014 1:06 PM
    viking99969 viking99969 Feb 19, 2014 5:57 PM Flag

    No, you aren't missing anything - the numbers don't work for the immediate future and any longs should take their winnings as this stock won't support current sentiment for very long. Change at the top doesn't mean they can do anything about bettering the margins w/o new players of some sort, do you know anything in their pipeline that will replace Copaxone? I thought not........

  • Reply to

    A lot of you

    by bottomfeeder0103 Jan 29, 2014 1:45 PM
    viking99969 viking99969 Feb 3, 2014 6:54 PM Flag

    Oh, I'll watch but the odds of getting to $50 are so less than getting to $40 - I'd predict 10% compared 90%. It isn't that I don't support TEVA as an Israeli company or some such nonsense as that, it is just where they are in their cycle. They don't have experience in replacing a brand winner like Copaxone with another. In the meanwhile, we watch BIIB's drug capture the patent-protected part of this market.

    Sentiment: Sell

  • Reply to

    A lot of you

    by bottomfeeder0103 Jan 29, 2014 1:45 PM
    viking99969 viking99969 Jan 31, 2014 12:19 PM Flag

    So you think TEVA will be able to convince managed care or another payor-types that their "convenience" pricing will be low enuff long enuff for the covered patients to justify switching? Time to take the blinders off and see that TEVA is caught in the same fly-trap they have done to others so so many times. To argue to the contrary means TEVA margins are so thin as to have the same effect as being generic, the end result on earnings is the same.

    Sentiment: Sell

  • viking99969 viking99969 Jan 30, 2014 12:40 PM Flag

    Drink their Kook-Aid all you want but....this not a "different" molecule patent protected but just a different dosing schedule with hope of switching patients to it. Why would a payor or managed care want their covered patient switched? In a relative short time period, the mhc/payor will see dollar savings of 50% (patient will have a lower deductible out of pocket) to use exact same drug. Savings will outstrip convenience for most.

    Sentiment: Strong Sell

  • Reply to

    A lot of you

    by bottomfeeder0103 Jan 29, 2014 1:45 PM
    viking99969 viking99969 Jan 30, 2014 12:28 PM Flag

    Absolutely incorrect information as the dosing may be protected but not the actual active drug.

33.23+0.24(+0.73%)10:03 AMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.